Our findings provide novel insight into the association of ERα loss during endocrine therapy with enhanced invasive and metastatic ability of breast cancer cells and should aid in a more comprehensive understanding of the effects of endocrine therapy in clinical treatment. The gene discussed is ESR1; the disease is breast carcinoma.